441 related articles for article (PubMed ID: 22417707)
1. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
Datta I; Bhonde R
Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
[TBL] [Abstract][Full Text] [Related]
2. Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro.
Jin GZ; Cho SJ; Choi EG; Lee YS; Yu XF; Choi KS; Yee ST; Jeon JT; Kim MO; Kong IK
Cell Biol Int; 2008 Nov; 32(11):1433-8. PubMed ID: 18778785
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic neurons.
Chinta SJ; Andersen JK
Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior.
Park S; Kim E; Koh SE; Maeng S; Lee WD; Lim J; Shim I; Lee YJ
Brain Res; 2012 Jul; 1466():158-66. PubMed ID: 22634376
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease.
Chao YX; He BP; Tay SS
J Neuroimmunol; 2009 Nov; 216(1-2):39-50. PubMed ID: 19819031
[TBL] [Abstract][Full Text] [Related]
6. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
7. Gender segregation in gene expression and vulnerability to oxidative stress induced injury in ventral mesencephalic cultures of dopamine neurons.
Tao Q; Fan X; Li T; Tang Y; Yang D; Le W
J Neurosci Res; 2012 Jan; 90(1):167-78. PubMed ID: 21919034
[TBL] [Abstract][Full Text] [Related]
8. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
Glavaski-Joksimovic A; Virag T; Chang QA; West NC; Mangatu TA; McGrogan MP; Dugich-Djordjevic M; Bohn MC
Cell Transplant; 2009; 18(7):801-14. PubMed ID: 19796495
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
10. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of nigral cell death in Parkinson's disease.
Przedborski S
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells and neuroregeneration in Parkinson's disease.
Glavaski-Joksimovic A; Bohn MC
Exp Neurol; 2013 Sep; 247():25-38. PubMed ID: 23542820
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.
Liang CL; Wang TT; Luby-Phelps K; German DC
Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972
[TBL] [Abstract][Full Text] [Related]
14. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
15. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.
Somoza R; Juri C; Baes M; Wyneken U; Rubio FJ
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1530-40. PubMed ID: 20542127
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
17. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
Isacson O; Bjorklund LM; Schumacher JM
Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs.
Seroogy KB; Lundgren KH; Tran TM; Guthrie KM; Isackson PJ; Gall CM
J Comp Neurol; 1994 Apr; 342(3):321-34. PubMed ID: 7912699
[TBL] [Abstract][Full Text] [Related]
19. Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line-derived neurotrophic factor.
Chun HS; Yoo MS; DeGiorgio LA; Volpe BT; Peng D; Baker H; Peng C; Son JH
Exp Neurol; 2002 Feb; 173(2):235-44. PubMed ID: 11822887
[TBL] [Abstract][Full Text] [Related]
20. Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP-induced oxidative stress.
Rieker C; Schober A; Bilbao A; Schütz G; Parkitna JR
Eur J Neurosci; 2012 Mar; 35(5):735-41. PubMed ID: 22356487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
